Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small cell lung cancer

British Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 257-262

  Yokoyama, A ^a   Kurita, Y ^a   Saijo, N ^b   Tamura, T ^c   Noda, K ^d   Shimokata, K ^e   Matsuda, T ^f  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAZAWA UNIVERSITY   (Japan)

Author keywords

Combined modality therapy; Irinotecan; Non small cell lung cancer; Radiation therapy

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; ESOPHAGITIS; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; VOMITING;

EID: 0031811975     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.474     Document Type: Article

References (26)

1. Baker L, Khan R, Lynch T, Savaraj N, Sandler A, Feun L, Schaserr, Hanover C and Petit R (1997) Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) (abstract 1658). Proc Am Soc Clin Oncol 16: 461a
2. Boothman DA, Trask DK and Pardee AB (1989) Inhibition of potentially lethal DNA damage repair in human tumor cells by B-lapachone. an activator of topoisomerase I. Cancer Res 49; 605-612
3. Devore R, Crawford J, Dimery I, Eckardt J, Eckardt D, Kasunic D, Demke D and Gorris G (1997) Phase II trial of irinotecan (CPT-II) plus cisplatin (CDDP) in advanced NSCLC (abstract 1674). Proc Am Soc Clin Oncol. 16: 466a
4. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei III EF and Green MR (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323; 940-945
5. Dillman RO, Herndon J, Seagren SL, Eaton Jr WL, Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215
6. Douillard JY, Ibrahim N, Riviere A, Spaeth D, Chomy P, Soussan K and Mathieu-Bouc A (1995) Phase II study of CPT-11 (irinotecan) in non small cell lung cancer (NSCLC) (abstract 1118). Proc Am Soc Clin Oncol 14: 365
7. Falk SJ and Smith PJ (1992) DNA damaging and cell cycle effect of topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol 61: 749-757
8. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S and Taguchi T for the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-11. a new derivative of camptothecin, for previously untreated non-small-cell lung cancel. J Clin Oncol 10: 16-20
9. Furuse K, Fukuoka M, Takada Y, Nishiwaki H, Katagami N and Ariyoshi Y, for the West Japan Lung Cancer Group (1997) A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCTC): preliminary analysis, (abstract 1649). Proc Am Soc Clin Oncol 16: 459a
10. Greco FA, Stroup SL, Gray JR and Hainsworth JD (1996) Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 14: 1642-1648
11. Jeremic B, Shibamoto Y, Acimovic L and Milisavljevic S (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14: 1065-1070
12. Kim JH, Kim SH, Kolozsvary A and Khil MS (1992) Potentiation radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 22: 515-518
13. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier M-J, Douillard J-Y and Laplanche A (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417-423
14. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K and Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775-1780
15. McGinnis WL, Shaw EG, Jung S-H, Jett J, Stella P, Marschke R, Kugler J, Mailliard J, Wiesenfeld M, Frytak S, Kuross S and Poon M for the North Central Cancer Treatment Group (NCCTG) (1995) Results of phase III prospective randomized trial comparing standard thoracic radiation therapy (TRT) to twice-daily (BID) TRT +/- concomitant etposide-cisplatin (FP) chemotherapy in patients with unresectable stage IIIA/B non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 355
16. Nakagawa K, Fukuoka M, Niitani H and the CPT-11 Lung Cancer Study Group (1993) Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 12: 332
17. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H and Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168
18. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909
19. Pei Xin-Hai, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Tsuruta N, Mizuno K and Hara N (1997) Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-Cancer Drug 8: 231-237
20. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW, Perez-Tamayo R and Rotman M (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 59: 1874-1881
21. Reckzeh B, Merte H, Pfluger K-H, Pfab R, Wolf M and Havemann K (1996) Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 14: 1071-1076
22. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrist AT, Dar AR and Cox JD (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced. unresectable non-small-cell lung cancer. J Natl Cancer Inst 87: 198-205
23. Schaake-Koning C, Van Den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L, Sculier J-P, Vanzandwijk N and Bartelink H (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524-530
24. Tamura K, Takada M, Kawase I, Tada T, Kudoh S, Okishio K, Fukuoka M, Yamaoka N, Fujiwara Y and Yamakido M (1997) Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88: 218-223
25. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M, Soemasu K and Members of the Clinical Trial Review Committee of the Japan Clinical Oncology Group (1993) Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23: 250-257
26. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48: Geneva.